IMMX IMMIX BIOPHARMA
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 8 analyst firms say about IMMIX BIOPHARMA: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 6 months
Analyst view · last 6M
6 rated views · 8 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MGood · #62 in the index84
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8053
Recent analyst activity · last 90 days
Our tracked history has 8 reports on IMMX from 6 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 2 raised their price target, 1 lowered it and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Mizuho raised its target from $15.00 (set 30 Mar 2026) to $23.00 on 29 Oct 2026.
Last 6 months. Latest opinion per identifiable analyst within the last 6 months. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Bank of America Securities | Tazeen Ahmad | Buy | 18 Jun 2026 | 27.00 USD |
| Citigroup | Unnamed analyst | Buy | 30 Sep 2026 | — |
| H.C. Wainwright | Robert Burns | Buy | 10 Aug 2026 | 25.00 USD |
| Lifesci Capital | Patrick Dolezal | Buy | 17 Jun 2026 | 19.00 USD |
| Mizuho | Graig Suvannavejh | — | 29 Oct 2026 | 23.00 USD |
| Morgan Stanley | Sean Laaman | Buy | 20 Oct 2026 | — |
| Needham | Gil Blum | Buy | 29 Sep 2026 | 30.00 USD |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:11 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.